Author highlights IMVT's $50 price target from Wolfe Research, 100% upside, additional buy ratings, a $350 million insider buy, and 20% short float ahead of phase 3 results.
IMVT — LONG The author notes Immunovant received a $50 price target from Wolfe Research, implying 100% upside from the current ~$25 level. Additional buy analyst ratings and a $350 million insider buy are cited as bullish signals ahead of phase 3 results. The 20% short float is mentioned as potential fuel for a squeeze.
IMVT👈GOT TARGET 50 from Wolfe Research ! now she in 25 area its 100 % upside ! 💥 + MORE BUY ANALYST RATE TODAY ! and 350 Million insider Buy ! before phase 3 results !
This Reddit post, published January 09, 2026, features u/BOOMHOTSTOCKS discussing IMVT. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/BOOMHOTSTOCKS · Tickers: IMVT